
ATP (Apple Tree Partners)
Financial History
Leadership Team
Key people at ATP (Apple Tree Partners).

Key people at ATP (Apple Tree Partners).
Key people at ATP (Apple Tree Partners).
Apple Tree Partners (ATP) is a leading venture capital firm specializing in life sciences, particularly in creating and investing in transformative biotechnology companies. Founded in 1999, ATP manages $2.9 billion in committed capital and operates from offices in New York, South San Francisco, and Cambridge, MA. The firm invests across all stages, from pre-IP scientific ideas to asset spinouts, supporting companies from seed stage through IPO and beyond. ATP’s mission centers on providing flexible capital and strategic, operational resources to build sustainable, research-driven enterprises that improve human health. Their portfolio includes companies developing novel therapeutics and medical devices targeting oncology, metabolic, inflammatory, and pulmonary diseases, reflecting a strong impact on the biotech startup ecosystem by fostering innovation and commercialization of cutting-edge life sciences technologies[1][2][5].
Apple Tree Partners was founded in 1999 by Dr. Seth Harrison and other key partners, evolving into a prominent life sciences venture capital firm with a unique model that combines capital provision with hands-on operational support. Over time, ATP has expanded its focus to include AI and machine learning applications in drug discovery, exemplified by initiatives like Deep Apple Therapeutics. The firm has been instrumental in launching over 30 life sciences companies, with 19 having gone public or been acquired, demonstrating a track record of successful exits and value creation. ATP’s evolution reflects a deepening integration of scientific expertise and entrepreneurial rigor to accelerate the development of transformative biotech enterprises[2][5][7].
ATP rides the wave of increasing convergence between biotechnology and advanced computational technologies like AI and machine learning, which are transforming drug discovery and development. The timing is critical as the biotech sector experiences rapid innovation cycles and growing demand for novel therapies addressing unmet medical needs. Market forces such as rising healthcare challenges, regulatory support for innovation, and expanding global biotech ecosystems favor ATP’s model. By creating and scaling research-driven companies, ATP influences the broader life sciences ecosystem, accelerating the translation of scientific breakthroughs into impactful therapies and medical technologies[5][6].
Looking ahead, Apple Tree Partners is poised to deepen its integration of AI and computational methods in biotech, expanding its portfolio in precision medicine and novel therapeutic areas. Trends such as personalized medicine, digital health convergence, and advanced biologics will likely shape their investment focus. ATP’s influence is expected to grow as it continues to pioneer flexible capital deployment combined with operational expertise, helping startups overcome traditional biotech development hurdles. This positions ATP as a critical enabler of next-generation life sciences innovation, sustaining its leadership role in the venture capital landscape[5].
In summary, Apple Tree Partners stands out as a venture capital firm that not only funds but actively builds transformative biotech companies, leveraging deep scientific expertise and operational support to improve human health outcomes.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2025 | Galvanize Therapeutics | $100.0M Series C | — | Jonathan Waldstreicher, Seth L. Harrison, Norwest Venture Partners, Soffinova Partners |
| Jul 1, 2025 | BloodFlow | $1.0M Seed | — | — |
| Aug 1, 2024 | Red Queen Therapeutics | $55.0M Series A | — | Joseph A. Yanchik III, Michael Ehlers, Paul Da Silva Jardine, Paul Eisenberg, Seth L. Harrison, Spiros Liras |
| Dec 1, 2023 | Deep Apple Therapeutics | $52.0M Series A | — | Michael Ehlers, Paul Da Silva Jardine, Paul Eisenberg, Seth L. Harrison, Spiros Liras |
| Nov 1, 2023 | Ascidian Therapeutics | $40.0M Series A | — | Michael Ehlers, Spiros Liras |
| Jul 1, 2023 | Aulos Bioscience | $20.0M Series A | — | Seth L. Harrison, Spiros Liras |
| Apr 1, 2023 | Initial Therapeutics | $75.0M Series A | — | Michael Ehlers, Paul Da Silva Jardine, Seth L. Harrison |
| Jan 1, 2023 | Aethon Therapeutics | $30.0M Series A | — | Michael Ehlers |
| Oct 1, 2022 | Ascidian Therapeutics | $50.0M Series A | — | Seth L. Harrison |
| Sep 1, 2022 | Galvanize Therapeutics | $100.0M Series B | — | Jonathan Waldstreicher, Seth L. Harrison, Norwest Venture Partners, Soffinova Partners |
| Dec 1, 2021 | Adendra Therapeutics | $53.0M Series A | — | Joseph A. Yanchik III, Michael Ehlers |
| Nov 1, 2021 | Marengo Therapeutics | $80.0M Series B | — | Michael Ehlers |
| Oct 1, 2021 | Intergalactic Therapeutics | $75.0M Series A | — | Joseph A. Yanchik III, Michael Ehlers, Seth L. Harrison, Spiros Liras |
| Sep 1, 2021 | Replicate Bioscience | $40.0M Series A | — | Michael Ehlers, Seth L. Harrison, Spiros Liras |
| Mar 1, 2021 | Galaxy Medical | $10.0M Series A | — | — |
| Jan 1, 2021 | Aulos Bioscience | $40.0M Series A | — | Seth L. Harrison, Spiros Liras |
| Nov 1, 2020 | Nereid Therapeutics | $50.0M Series A | — | Abingworth, Seth L. Harrison, Reinhard Ambros |
| Jun 1, 2020 | Nine Square Therapeutics | $50.0M Series A | — | — |
| Oct 1, 2014 | Aileron Therapeutics | $33.0M Series E | — | Abingworth |
| Nov 1, 2013 | Aileron Therapeutics | $30.0M Series E | — | Abingworth |
| May 1, 2013 | Eledon Pharmaceuticals | $36.0M Series E | — | — |
| Jan 1, 2013 | Aileron Therapeutics | $12.0M Series D | — | Abingworth |
| Sep 1, 2011 | Eledon Pharmaceuticals | $23.0M Series D | — | — |
| Jun 1, 2009 | Aileron Therapeutics | $40.0M Series D | — | Abingworth |
| Jun 1, 2009 | Eledon Pharmaceuticals | $22.0M Series D | — | — |